drugset / Trial / NCT01973790

Phase III, Long-term, Open-label Safety Study of Z-338

NCT01973790

Phase 3 Completed 207 enrolled Zeria Pharmaceutical
NaSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to evaluate the long-term safety of 100 mg Z-338 TID in European subjects with FD.

Timeline

Start
2014-03
Primary completion
2016-11
Completion
2017-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Acotiamide Small molecule 100 mg

Indications